https://www.selleckchem.com/pr....oducts/mitoquinone-m
We made comments on experimental model selection, experimental design and results, formulating the gaps of knowledge still existing such as the lack of reliable predictive biomarkers of tumour response to chemoradiation according to the molecular tumour subtype and lack of efficient radiosensitising agents specifically targeting bladder tumour cells. We provided guidance to improve forthcoming studies, such as taking into account molecular characteristics of the preclinical models and highlighted the value of using patient-